In the MC38 allograft mouse model, knockout of METTL3 in tumor cells or treatment with STM2457, a highly potent and selective inhibitor of METTL3, synergistically enhances the efficacy of anti-PD-1 therapy, significantly reducing MDSC infiltration and increasing CD8 + T cell infiltration. Here, CD8A is linked to neoplasm.